Document Detail


Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
MedLine Citation:
PMID:  19546865     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
FDA approval of the multitargeted, antiangiogenic tyrosine kinase inhibitors (TKIs) sunitinib and sorafenib, and the serine and threonine mammalian target of rapamycin inhibitor, temsirolimus, has revolutionized the management of metastatic clear-cell renal-cell carcinoma (CC-RCC). The inability of these targeted therapies to provide durable complete responses, however, is a serious limiting factor to their clinical usefulness. Although immunotherapeutic approaches in advanced disease are increasingly regarded as a historical treatment paradigm, we propose that a fundamental understanding of immunobiology in CC-RCC can improve the selection of patients for high-dose intravenous interleukin 2 and facilitate the development of novel immunotherapeutic strategies. In our opinion, immunotherapeutic strategies have an important place in the management of advanced CC-RCC in the era of biological targeted therapy.
Authors:
Swethajit Biswas; Tim Eisen
Related Documents :
18089685 - Long-term outcome of chinese patients with membranous lupus nephropathy.
9205155 - Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.
7314355 - Osseous metastases secondary to renal cell carcinoma.
18998055 - Blackberry-induced hand-foot skin reaction to sunitinib.
22237265 - Defining local-regional control and its importance in locally advanced non-small cell l...
10592105 - Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-re...
Publication Detail:
Type:  Journal Article; Review     Date:  2009-06-23
Journal Detail:
Title:  Nature reviews. Clinical oncology     Volume:  6     ISSN:  1759-4782     ISO Abbreviation:  -     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-31     Completed Date:  2009-10-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500077     Medline TA:  Nat Rev Clin Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  478-87     Citation Subset:  IM    
Affiliation:
Freeman Hospital, Newcastle upon Tyne, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use
Antigens, Neoplasm / analysis
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cancer Vaccines / therapeutic use
Carbonic Anhydrases / analysis
Carcinoma, Renal Cell / blood supply,  drug therapy,  immunology,  secondary*,  therapy
Clinical Trials as Topic / statistics & numerical data
Combined Modality Therapy
Cytokines / therapeutic use
Drug Delivery Systems
Humans
Immunoconjugates / therapeutic use
Immunotherapy*
Infusions, Intravenous
Interferon-alpha / administration & dosage,  therapeutic use*
Interleukin-2 / administration & dosage,  therapeutic use*
Kidney Neoplasms / blood supply,  drug therapy,  immunology,  pathology,  therapy*
Meta-Analysis as Topic
Neoplasm Proteins / immunology,  physiology
Patient Selection
Protein Kinase Inhibitors / therapeutic use
T-Lymphocyte Subsets / drug effects,  immunology
Tumor Markers, Biological / analysis
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/Cancer Vaccines; 0/Cytokines; 0/Immunoconjugates; 0/Interferon-alpha; 0/Interleukin-2; 0/Neoplasm Proteins; 0/Protein Kinase Inhibitors; 0/Tumor Markers, Biological; EC 4.2.1.1/CA9 protein, human; EC 4.2.1.1/Carbonic Anhydrases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitative imaging biomarkers in neuro-oncology.
Next Document:  Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation.